Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
09 2019
Historique:
received: 26 02 2019
accepted: 31 07 2019
entrez: 10 9 2019
pubmed: 10 9 2019
medline: 14 7 2020
Statut: ppublish

Résumé

The World Health Organization, while recommending pre-exposure prophylaxis (PrEP) for HIV-negative pregnant and postpartum women in HIV high-burden settings, advocates for continued safety evaluation of PrEP in this population. The PrEP Implementation in Young Women and Adolescents (PrIYA) program delivered PrEP to pregnant and postpartum women integrated within routine maternal and child health clinics (MCH) at 16 sites in Western Kenya. PrEP exposure and perinatal outcome data were collected among women obtaining postnatal services during programme evaluation. PrEP use was self-reported and confirmed with clinical records. Perinatal outcomes including gestational age at birth, birthweight, congenital malformations and infant growth outcomes were abstracted from clinical records for mother-infant pairs attending the six week visit. Associations between infant outcomes and maternal prenatal PrEP use were assessed using univariate and multivariate logistic and linear regression. The PrIYA evaluation identified 1530 postpartum mother-infant pairs with data on prenatal PrEP exposure: 206 with prenatal PrEP use, 1324 without. Median maternal age was 24 years in both groups. PrEP users (any reported PrEP use) were significantly more likely to report HIV risk factors such as: intimate partner violence, sexually transmitted infections and having a partner with positive or unknown HIV status. Most mothers initiated PrEP during the second trimester (n = 116, 57%) and used PrEP for more than one month (n = 110, 58%). The mean birthweight was 3.3 kg and gestational age at birth was 38.5 weeks in both groups. There were no major differences between PrEP exposed and unexposed infants in rates of preterm birth and low birthweight. There were no congenital malformations identified in the PrEP-exposed group and five reported in the PrEP unexposed group. At six weeks postpartum, infants in both groups had similar growth. No differences in infant outcomes were found by duration PrEP exposure, trimester of PrEP initiation, a subset analysis of women 15 to 24 years old or in multivariate analyses. This analysis demonstrates that monitoring of infant outcomes is feasible within large-scale programmatic implementation of PrEP among pregnant and postpartum populations. Pregnancy outcomes and early infant growth did not differ by PrEP exposure.

Identifiants

pubmed: 31498563
doi: 10.1002/jia2.25378
pmc: PMC6733245
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25378

Subventions

Organisme : NIMH NIH HHS
ID : R00 MH118134
Pays : United States
Organisme : NIMH NIH HHS
ID : K99 MH118134
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002318
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002317
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Sex Health. 2018 Nov;15(6):501-512
pubmed: 30447703
AIDS. 2012 Jun 1;26(9):1151-9
pubmed: 22382151
J Acquir Immune Defic Syndr. 2017 Sep 01;76(1):1-12
pubmed: 28291053
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
Curr Opin HIV AIDS. 2016 Jan;11(1):18-26
pubmed: 26417954
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):417-25
pubmed: 22193774
PLoS One. 2015 Apr 17;10(4):e0122433
pubmed: 25886375
PLoS Med. 2016 Sep 27;13(9):e1002133
pubmed: 27676386
J Infect Dis. 2017 Dec 19;216(12):1561-1568
pubmed: 29040666
BMJ. 2010 Dec 22;341:c6580
pubmed: 21177735
AIDS Patient Care STDS. 2016 Mar;30(3):119-24
pubmed: 27308805
N Engl J Med. 2016 Nov 3;375(18):1726-1737
pubmed: 27806243
PLoS One. 2015 May 05;10(5):e0125525
pubmed: 25942423
AIDS. 2017 Jan 14;31(2):213-232
pubmed: 27831952
Glob Health Sci Pract. 2018 Jun 29;6(2):249-256
pubmed: 29959270
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
BMJ Open. 2019 Mar 7;9(3):e025122
pubmed: 30850409
PLoS Med. 2012;9(5):e1001217
pubmed: 22615543
JAMA. 2014 Jul 23-30;312(4):362-71
pubmed: 25038355
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):333-43
pubmed: 26918545
AIDS. 2018 Jul;32(12):1707-1713
pubmed: 30001244
J Int AIDS Soc. 2019 Sep;22(9):e25378
pubmed: 31498563

Auteurs

Julia C Dettinger (JC)

Department of Global Health, University of Washington, Seattle, WA, USA.

John Kinuthia (J)

Department of Global Health, University of Washington, Seattle, WA, USA.
Department of Obstetrics/Gynecology, Kenyatta National Hospital, Nairobi, Kenya.

Jillian Pintye (J)

Department of Global Health, University of Washington, Seattle, WA, USA.

Felix Abuna (F)

University of Washington - Kenya, Nairobi, Kenya.

Emily Begnel (E)

Department of Global Health, University of Washington, Seattle, WA, USA.

Kenneth Mugwanya (K)

Department of Global Health, University of Washington, Seattle, WA, USA.

Joseph Sila (J)

University of Washington - Kenya, Nairobi, Kenya.

Harison Lagat (H)

University of Washington - Kenya, Nairobi, Kenya.

Jared M Baeten (JM)

Department of Global Health, University of Washington, Seattle, WA, USA.
Department of Epidemiology, University of Washington, Seattle, WA, USA.
Department of Medicine, University of Washington, Seattle, WA, USA.

Grace John-Stewart (G)

Department of Global Health, University of Washington, Seattle, WA, USA.
Department of Epidemiology, University of Washington, Seattle, WA, USA.
Department of Medicine, University of Washington, Seattle, WA, USA.
Department of Pediatrics, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH